Cargando…
Is Pathologic Complete Response the Surrogate in Primary Gastric Angiosarcoma Undergoing Doxorubicin-Based Neoadjuvant Chemotherapy? A Case Report
INTRODUCTION: Angiosarcoma is a malignant tumor with low incidence. Especially in the advanced tumors, there is still a lack of knowledge of evidence-based medicine. CASE PRESENTATION: We report a case of a 55-year-old woman with abdominal pain of 2 months of duration, which had increased in severit...
Autores principales: | Zheng, Chun-Hui, Wang, Yang, Liu, Ting-Ting, Ding, Xiao-Yan, Qu, Jian-Jun, Su, Zhi-De |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754096/ https://www.ncbi.nlm.nih.gov/pubmed/33363400 http://dx.doi.org/10.2147/IJGM.S280375 |
Ejemplares similares
-
Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy
por: Li, JunJie, et al.
Publicado: (2016) -
Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer
por: Hu, Shen-Bao, et al.
Publicado: (2019) -
Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer
por: Chen, Yong-He, et al.
Publicado: (2020) -
Neoadjuvant Systemic Treatment of Primary Angiosarcoma
por: Heinhuis, Kimberley M., et al.
Publicado: (2020) -
Prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer using a deep learning (DL) method
por: Qu, Yu‐Hong, et al.
Publicado: (2020)